The fine-tuning of anti-oxidized low-density lipoprotein antibodies in cardiovascular disease and thrombosis.

Abstract

Anti-oxidised low-density lipoprotein (anti-oxLDL) antibodies are a heterogeneous group of autoantibodies including both pathogenic and protective subsets. Whereas in most studies the levels of anti-oxLDL antibodies were associated with enhanced atherosclerosis as evaluated by different methods, immunization with oxLDL leads to elevated levels of anti-oxLDL and protection against atherosclerosis. Anti-oxLDL can also be used for immunomodulation of atherosclerosis (i.e. possible therapeutic use of intravenous immunoglobulin, oral tolerance). More specific autoantibodies out of total anti-oxLDL should be selected, for instance, anti-oxLDL/beta-2-glycoprotein I complex, hence defining the fine-tuning of anti-oxLDL antibodies might detect which autoantibodies are pathogenic and which can be used therapeutically.

• Authors: Jozélio Freire de Carvalho, Yaniv Sherer, Yehuda Shoenfeld
• Journal: Thrombosis and haemostasis (Thromb Haemost) Vol. 98 Issue 6 Pg. 1157-9 (Dec 2007) ISSN: 0340-6245 [Print] Germany
• PMID: 18064307 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Autoantibodies
• Cardiovascular Agents
• Immunoglobulins, Intravenous
• Lipoproteins, LDL
• oxidized low density lipoprotein

Topics

• Animals
• Atherosclerosis (immunology, therapy)
• Autoantibodies (blood)
• Cardiovascular Agents (therapeutic use)
• Epitope Mapping
• Humans
• Immune Tolerance
• Immunoglobulins, Intravenous (therapeutic use)
• Immunotherapy (methods)
• Lipoproteins, LDL (immunology)
• Thrombosis (immunology)